WO2014203198A3 - Compositions and methods for the treatment of neurological diseases and renal complications - Google Patents
Compositions and methods for the treatment of neurological diseases and renal complications Download PDFInfo
- Publication number
- WO2014203198A3 WO2014203198A3 PCT/IB2014/062442 IB2014062442W WO2014203198A3 WO 2014203198 A3 WO2014203198 A3 WO 2014203198A3 IB 2014062442 W IB2014062442 W IB 2014062442W WO 2014203198 A3 WO2014203198 A3 WO 2014203198A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- compositions
- renal
- methods
- neurological diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological diseases and renal complications may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of renal transplantation, preservation of renal function in rhabdomyolysis secondary to crush injuries and compartment syndrome, Bowel preparation before colorectal surgery, colonoscopy, and barium enemas, promotion of urinary excretion of toxic material, chronic Pain, diabetic neuropathy, seizures, Creutzfeld- Jacob disease, multiple sclerosis, Parkinson's, Obesity, bipolar depression, partial-onset seizures and spasm.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2711/CHE/2013 | 2013-06-22 | ||
| IN2711CH2013 | 2013-06-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2014203198A2 WO2014203198A2 (en) | 2014-12-24 |
| WO2014203198A3 true WO2014203198A3 (en) | 2015-04-02 |
Family
ID=52105417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2014/062442 Ceased WO2014203198A2 (en) | 2013-06-22 | 2014-06-19 | Compositions and methods for the treatment of neurological diseases and renal complications |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2014203198A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7346571B2 (en) * | 2018-12-05 | 2023-09-19 | ビー．ジー．ネゲブ テクノロジーズ アンド アプリケーションズ リミテッド， アット ベン‐グリオン ユニバーシティー | Sugar-conjugated L-DOPA and/or DOPA decarboxylase inhibitors for the treatment of dopamine-responsive disorders |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008101309A1 (en) * | 2007-02-20 | 2008-08-28 | Multi Formulations Ltd. | Creatine-fatty acids |
| WO2008101310A1 (en) * | 2007-02-20 | 2008-08-28 | Multi Formulations Ltd. | Creatine-fatty acids |
| WO2012149352A1 (en) * | 2011-04-29 | 2012-11-01 | Catabasis Pharmaceuticals, Inc. | Fatty acid guanidine and salicylate guanidine derivatives and their uses |
-
2014
- 2014-06-19 WO PCT/IB2014/062442 patent/WO2014203198A2/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008101309A1 (en) * | 2007-02-20 | 2008-08-28 | Multi Formulations Ltd. | Creatine-fatty acids |
| WO2008101310A1 (en) * | 2007-02-20 | 2008-08-28 | Multi Formulations Ltd. | Creatine-fatty acids |
| WO2012149352A1 (en) * | 2011-04-29 | 2012-11-01 | Catabasis Pharmaceuticals, Inc. | Fatty acid guanidine and salicylate guanidine derivatives and their uses |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014203198A2 (en) | 2014-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009039397A3 (en) | Substituted amides, methods of making, use thereof for the treatment of diseases such as cancer | |
| WO2009029622A3 (en) | Antiviral drugs for treatment of arenavirus infection | |
| WO2007133637A3 (en) | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | |
| WO2015017813A3 (en) | Inhibitors of the farnesoid x receptor and uses in medicine | |
| WO2008040548A3 (en) | Treatment for non-alcoholic-steatohepatitis | |
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| WO2013123215A3 (en) | Antiviral drugs for treatment of arenavirus infection | |
| WO2013175377A3 (en) | Compositions and methods for treatment of mucositis | |
| MD4436B1 (en) | Compounds for the treatment of addiction | |
| HK1214968A1 (en) | A novel composition for nonalcoholic fatty liver disease (nafld) | |
| WO2007093183A3 (en) | Use of a compound that enhances gabaa-ergic neurotransmission for the treatment of inflammatory diseases | |
| WO2008119057A3 (en) | The use of pde7 inhibitors for the treatment of movement disorders | |
| WO2008079610A3 (en) | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome | |
| EP2215054B8 (en) | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | |
| WO2016127168A3 (en) | Mebendazole polymorph for treatment and prevention of tumors | |
| WO2014068463A3 (en) | Compositions and methods for the treatment of inflammation and metabolic disorders | |
| CL2008000554A1 (en) | COMPOUNDS DERIVED FROM REPLACED DIAMINOPIRIMIDINE; METHOD OF PREPARATION OF SUCH COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND FOR THE TREATMENT OF AN URINARY TRACT DISEASE, A PAINFUL PATHOLOGICAL STATE, A DISORDER RES | |
| WO2014087307A3 (en) | Compositions and methods for the treatment of metabolic syndrome and diabetes | |
| WO2010046273A3 (en) | Pyrimidinyl pyridone inhibitors of jnk | |
| WO2014091384A3 (en) | Compositions and methods for the treatment of mucositis | |
| WO2014160940A3 (en) | Lipidic furan, pyrrole, and thiophene compounds for treatment of cancer, neurological disorders, and fibrotic disorders | |
| WO2013175359A3 (en) | Compositions and methods for the treatment of multiple sclerosis | |
| WO2014203198A3 (en) | Compositions and methods for the treatment of neurological diseases and renal complications | |
| WO2014195850A3 (en) | Compositions and methods for the treatment of neurologic diseases and neurological disorders | |
| WO2014087323A3 (en) | Compounds and compositions for the treatment of autoimmune and chronic metabolic diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 14814638 Country of ref document: EP Kind code of ref document: A2 |